Interview: Stefan Braam – CEO, Pluriomics, The Netherlands
Stem cell technology can play a key role in improving the drug discovery process. The CEO of Pluriomics, a biotech company focused on development of fully functional human assay systems…
Pluriomics is an emerging biotechnology company whose mission is to deliver innovative human cardiomyocyte models for use in drug discovery & development. Pluriomics ambition is to implement its cardiomyocyte models at various stages of drug discovery to improve decision-making, reduce attrition rates and provide an alternative for animal testing. Pluriomics, with offices in Leiden, The Netherlands and production facilities in Gosselies, Belgium was founded in 2010. Its Pluricyte cardiomyocyte models are derived from induced pluripotent stem cells and based upon patented technologies.
Contact
Pluriomics BV
Biopartner building 3
Galileiweg 8
2333 BD Leiden
The Netherlands
pluriomics.com
Stem cell technology can play a key role in improving the drug discovery process. The CEO of Pluriomics, a biotech company focused on development of fully functional human assay systems…
See our Cookie Privacy Policy Here
